Loading
A phase 2 trial of Carmustine, Mercaptopurine and Streptozocin in Oligodendroglioma, IDH-mutant and 1p/19q-codeleted and Glioma & glioblastoma, run by Emory University, completed.
Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms is a phase 2 interventional study registered as NCT00004688 by Emory University, with 35 participants recorded, started 1996-08. Interventions recorded: carmustine, mercaptopurine, streptozocin. Conditions recorded: Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Mixed Gliomas, Glioblastoma Multiforme, Recurrent Brain Tumor.
Linked to the drug Streptozocin because the registry names it among its interventions and Oligodendroglioma, IDH-mutant and 1p/19q-codeleted and Glioma & glioblastoma among its conditions. Registry record only: no result has been read by an editor.
Shares Streptozocin and the tag pipeline.
Shares Carmustine, Glioma & glioblastoma and the tag pipeline.
Shares Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.